| |
| |
|
| Insider
Information: |
Hoffman Stephen J |
| Relationship: |
Director |
| City: |
Carlisle |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
7 |
|
| Direct
Shares |
64,385 |
|
|
Indirect Shares
|
6,603,592 |
|
|
| Direct
Value |
$62,564 |
|
|
|
Indirect Value
|
$70,416,707 |
|
|
| Total
Shares |
6,667,977 |
|
|
| Total
Value |
$70,479,272 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Allos Therapeutics Inc |
ALTH |
Director |
2012-09-04 |
0 |
2012-09-04 |
0 |
Premium* |
|
|
Dicerna Pharmaceuticals Inc |
DRNA |
Director |
2021-12-28 |
0 |
2014-02-04 |
1,734,751 |
Premium* |
|
|
Genocea Biosciences, Inc. |
GNCA |
Director |
2014-02-10 |
0 |
2015-03-17 |
1,992,415 |
Premium* |
|
|
Acelrx Pharmaceuticals Inc |
ACRX |
Director |
2023-10-10 |
2,418 |
2014-03-07 |
2,871,933 |
Premium* |
|
|
Tetraphase Pharmaceuticals Inc |
TTPH |
10% Owner |
2014-03-12 |
0 |
2014-03-12 |
4,493 |
Premium* |
|
|
Aadi Bioscience, Inc |
AADI |
Chief Executive Office... |
2018-11-12 |
31,967 |
2018-11-09 |
0 |
Premium* |
|
|
Research Alliance Corp. Ii |
RACB |
Director |
2021-03-17 |
30,000 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
43 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 2
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| RACB |
Research Alliance Corp. I... |
Director |
– • – |
2021-03-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
30,000 |
|
- |
|
| ALTH |
Allos Therapeutics Inc |
Director |
– • – |
2009-12-23 |
5/A |
GD |
$0.00 |
$0 |
D/D |
472,871 |
2,000 |
0 |
- |
|
| ALTH |
Allos Therapeutics Inc |
Director |
– • – |
2009-12-23 |
5/A |
GA |
$0.00 |
$0 |
I/I |
472,871 |
472,871 |
0 |
- |
|
| ALTH |
Allos Therapeutics Inc |
Director |
– • – |
2009-12-23 |
5 |
GD |
$0.00 |
$0 |
D/D |
224,871 |
249,999 |
0 |
- |
|
| ALTH |
Allos Therapeutics Inc |
Director |
– • – |
2009-12-23 |
5 |
GA |
$0.00 |
$0 |
I/I |
224,871 |
224,871 |
0 |
- |
|
| ALTH |
Allos Therapeutics Inc |
Director |
– • – |
2011-12-13 |
4 |
A |
$0.00 |
$0 |
D/D |
90,000 |
339,999 |
0 |
- |
|
| DRNA |
Dicerna Pharmaceuticals I... |
Director |
– • • |
2014-02-04 |
4 |
A |
$0.00 |
$0 |
I/I |
1,534,751 |
1,534,751 |
0 |
- |
|
| GNCA |
Genocea Biosciences, Inc. |
Director |
– • – |
2014-02-10 |
4 |
A |
$0.00 |
$0 |
I/I |
1,041,484 |
1,041,484 |
0 |
- |
|
| ACRX |
Acelrx Pharmaceuticals In... |
Director |
– • – |
2014-03-07 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,300,000) |
2,871,933 |
0 |
- |
|
| TTPH |
Tetraphase Pharmaceutical... |
10% Owner |
– – • |
2014-03-12 |
4 |
D |
$0.00 |
$0 |
I/I |
(300,000) |
1,890,146 |
0 |
- |
|
| TTPH |
Tetraphase Pharmaceutical... |
10% Owner |
– – • |
2014-03-12 |
4 |
A |
$0.00 |
$0 |
I/I |
4,493 |
4,493 |
0 |
- |
|
| ACRX |
Acelrx Pharmaceuticals In... |
Director |
– • – |
2019-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
3,750 |
3,750 |
0 |
- |
|
| ACRX |
Acelrx Pharmaceuticals In... |
Director |
– • – |
2020-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
7,500 |
11,250 |
0 |
- |
|
| DRNA |
Dicerna Pharmaceuticals I... |
Director |
– • – |
2021-06-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,333 |
29,071 |
0 |
- |
|
| ACRX |
Acelrx Pharmaceuticals In... |
Director |
– • – |
2021-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
21,250 |
0 |
- |
|
| ACRX |
Acelrx Pharmaceuticals In... |
Director |
– • – |
2022-07-15 |
4 |
A |
$0.00 |
$0 |
D/D |
15,500 |
36,750 |
0 |
- |
|
| ACRX |
Acelrx Pharmaceuticals In... |
Director |
– • – |
2023-10-10 |
4 |
A |
$0.00 |
$0 |
D/D |
581 |
2,418 |
0 |
- |
|
| ALTH |
Allos Therapeutics Inc |
Chariman of the Board |
• • – |
2005-05-25 |
4 |
OE |
$0.40 |
$129,995 |
D/D |
248,000 |
474,870 |
|
- |
|
| ALTH |
Allos Therapeutics Inc |
Director |
• • – |
2012-09-04 |
4 |
D |
$1.82 |
$862,081 |
I/I |
(473,671) |
0 |
0 |
- |
|
| ALTH |
Allos Therapeutics Inc |
Director |
• • – |
2012-09-04 |
4 |
D |
$1.82 |
$167,440 |
D/D |
(92,000) |
0 |
0 |
- |
|
| AADI |
Aadi Bioscience, Inc |
Chief Executive Officer |
• • – |
2018-11-09 |
4 |
B |
$1.95 |
$3,836 |
D/D |
1,967 |
1,967 |
2.73 |
- |
|
| AADI |
Aadi Bioscience, Inc |
Chief Executive Officer |
• • – |
2018-11-12 |
4 |
B |
$2.01 |
$60,300 |
D/D |
30,000 |
31,967 |
2.81 |
- |
|
| ALTH |
Allos Therapeutics Inc |
Director |
– • – |
2008-09-02 |
4 |
OE |
$2.42 |
$96,776 |
D/D |
40,000 |
514,870 |
0 |
- |
|
| ALTH |
Allos Therapeutics Inc |
Director |
– • – |
2009-02-04 |
4 |
OE |
$2.42 |
$88,066 |
D/D |
36,400 |
511,270 |
0 |
- |
|
| ALTH |
Allos Therapeutics Inc |
Director |
– • – |
2010-01-04 |
4 |
OE |
$2.42 |
$61,521 |
D/D |
25,428 |
500,298 |
0 |
- |
|
43 Records found
|
|
Page 1 of 2 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
